[release] Firalis and Celemics announce an agreement for the commercialization of a unique proprietary long non- coding RNA (lncRNA) panel, FiMICS®

Firalis S.A. (“Firalis”), a Huningue based developer and provider of biomarker products and bioanalytical services for research and diagnostic use and Celemics, Inc. (“Celemics”), a Seoul based provider of targeted enrichment of genomic technology for Next-Generation Sequencing (NGS) application, instruments and reagents for molecular biology, today announced a development and supply agreement (“Agreement”) that will enable Firalis to commercialize a Next-Generation Sequencing-based product “FiMICS" to quantify cardiac-enriched long non-coding RNAs (lncRNAs).